Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended March 31, 2004
Business Overview: Myriad is a biopharmaceutical company focused on predictive medicine products (e.g., BRACAnalysis, COLARIS) and the development of therapeutic drugs for cancer, Alzheimer's disease, and other conditions. The company operates three segments: Research, Predictive Medicine, and Drug Development.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Mar 31, 2004 | 9 Months Ended Mar 31, 2004 |
|---|---|---|
| Total Revenues | $13,756 | $41,576 |
| Net Loss | $(10,696) | $(30,159) |
| Loss Per Share (Basic & Diluted) | $(0.39) | $(1.11) |
| Cash and Cash Equivalents | $46,912 | $46,912 (as of Mar 31, 2004) |
| Total Marketable Securities | $52,171 | $52,171 (as of Mar 31, 2004) |
| Accumulated Deficit | $(128,810) | $(128,810) (as of Mar 31, 2004) |
| Net Cash Used in Operating Activities | N/A | $(24,395) |
Segment Performance (9 Months Ended Mar 31, 2004):
- Predictive Medicine: Revenue of $30.2 million; Operating Gain of $1.8 million.
- Research: Revenue of $11.4 million; Operating Loss of $(12.9) million.
- Drug Development: Revenue of $0; Operating Loss of $(20.6) million.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 14% for the three months and 15% for the nine months compared to the prior year periods. This was driven primarily by a 70% drop in research revenue (3 months) and a 51% drop (9 months) due to the completion of collaborations with DuPont and Hitachi.
- Predictive Medicine Growth: Predictive medicine revenue increased 26% (3 months) and 19% (9 months) year-over-year, attributed to increased sales efforts and wider medical acceptance of products.
- Expense Increases: Research and development (R&D) expenses rose 12% (3 months) and 13% (9 months). This increase was partially due to a $1.7 million one-time charge related to the settlement of a third-party dispute regarding royalties and fees.
- Liquidity: Cash, cash equivalents, and marketable securities decreased by $31.5 million (24%) from the prior year, reflecting capital expenditures for facilities and equipment and increased drug development spending.
Guidance, Outlook, and Risks
Outlook: Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials (including Phase 2/3 for Flurizan in prostate cancer and Phase 1/2 for Alzheimer's), and new product launches. The company believes existing capital resources are sufficient to fund operations for at least the next two years.
Risks and Contingencies:
- Clinical Trial Risks: Uncertainty regarding the success of clinical trials for therapeutic candidates.
- Regulatory Approval: Dependence on securing regulatory approval for new drugs and predictive medicine products.
- Collaboration Dependence: Future revenue is partly dependent on payments from collaborative agreements, which may fluctuate.
- Legal: Risks associated with patent infringement claims and the costs of enforcing intellectual property.
Unusual Items: The $1.7 million dispute settlement expense was included in R&D expenses for the period. Additionally, a related-party research agreement with Prolexys Pharmaceuticals was terminated effective January 26, 2004.
Investor Verification Checklist
- Dispute Settlement: Verify the finality of the $1.7 million third-party dispute settlement and confirm no further liabilities exist.
- Cash Burn Rate: Monitor the rate of cash consumption given the $24.4 million net cash used in operating activities over nine months and the lack of profitability.
- Clinical Trial Progress: Track the status of Flurizan clinical trials for prostate cancer and Alzheimer's disease as key drivers for future drug development revenue.
- Research Revenue Pipeline: Assess the company's ability to replace the significant revenue lost from the completed DuPont and Hitachi collaborations.
- Stock-Based Compensation: Note that reported net loss does not reflect stock-based compensation expense under FAS 123; pro forma losses are significantly higher (e.g., $(48.9) million for the nine months).